Comments
Loading...
Rapport sur les intérêts à découvert
L'intérêt à découvert sur Apellis Pharmaceuticals Inc (NASDAQ:APLS) a diminué lors de la dernière période de déclaration, augmentant de en baisse de 21.76M à 21.05M. Cela représente 21.95% des actions disponibles au public de l'entreprise.
L'intérêt à découvert pour Apellis Pharmaceuticals Corp (XNAS:APLS) a diminué au cours de la dernière période de référence, passant de 280,30 M à 275,20 M. Cela a mis 1,17 % des actions de la société disponibles au public en position courte.
Sur la base du volume moyen récent de 2.26M actions échangées par jour, il faudrait 9.31 jour(s) aux détenteurs de cet intérêt à découvert pour clôturer leurs positions sans faire monter brusquement le cours de l'action.
Intérêt à court terme
21.05M
Intérêt à court terme %
21.9%
Jours de couverture
9.31
Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|
APLS | Apellis Pharmaceuticals, Inc. | 09/30/2025 | 10/09/2025 | 21.95% | 95,884,373 | 21,047,108 | 2,261,845 | 9.31 | |
APLS | Apellis Pharmaceuticals, Inc. | 09/15/2025 | 09/24/2025 | 22.69% | 95,884,373 | 21,758,081 | 2,250,335 | 9.67 | |
APLS | Apellis Pharmaceuticals, Inc. | 08/29/2025 | 09/10/2025 | 21.42% | 95,884,373 | 20,539,985 | 1,769,177 | 11.61 | |
APLS | Apellis Pharmaceuticals, Inc. | 08/15/2025 | 08/26/2025 | 21.14% | 95,884,373 | 20,273,707 | 2,913,900 | 6.96 | |
APLS | Apellis Pharmaceuticals, Inc. | 07/31/2025 | 08/11/2025 | 23.04% | 95,884,373 | 22,092,024 | 3,044,053 | 7.26 | |
APLS | Apellis Pharmaceuticals, Inc. | 07/15/2025 | 07/24/2025 | 17.31% | 95,276,723 | 16,492,598 | 1,948,010 | 8.47 | |
APLS | Apellis Pharmaceuticals, Inc. | 06/30/2025 | 07/10/2025 | 27.45% | 95,276,723 | 26,148,815 | 1,867,422 | 14 | |
APLS | Apellis Pharmaceuticals, Inc. | 06/13/2025 | 06/25/2025 | 26.39% | 95,276,723 | 25,140,355 | 2,268,431 | 11.08 | |
APLS | Apellis Pharmaceuticals, Inc. | 05/30/2025 | 06/10/2025 | 26.28% | 95,276,723 | 25,034,198 | 2,513,498 | 9.96 | |
APLS | Apellis Pharmaceuticals, Inc. | 05/15/2025 | 05/27/2025 | 28.60% | 95,276,723 | 27,245,432 | 3,360,369 | 8.11 | |
APLS | Apellis Pharmaceuticals, Inc. | 04/30/2025 | 05/09/2025 | 30.20% | 95,276,723 | 28,771,303 | 2,263,456 | 12.71 | |
APLS | Apellis Pharmaceuticals, Inc. | 04/15/2025 | 04/25/2025 | 28.16% | 95,276,723 | 26,833,210 | 3,081,613 | 8.71 | |
APLS | Apellis Pharmaceuticals, Inc. | 03/31/2025 | 04/09/2025 | 24.48% | 91,955,446 | 22,511,249 | 2,165,571 | 10.4 | |
APLS | Apellis Pharmaceuticals, Inc. | 03/14/2025 | 03/25/2025 | 21.00% | 91,955,446 | 19,313,821 | 1,465,315 | 13.18 | |
APLS | Apellis Pharmaceuticals, Inc. | 02/28/2025 | 03/11/2025 | 22.64% | 91,955,446 | 20,815,049 | 1,738,206 | 11.98 | |
APLS | Apellis Pharmaceuticals, Inc. | 02/14/2025 | 02/26/2025 | 19.09% | 90,832,650 | 17,341,085 | 1,439,758 | 12.04 | |
APLS | Apellis Pharmaceuticals, Inc. | 01/31/2025 | 02/11/2025 | 18.78% | 90,832,650 | 17,055,810 | 1,473,551 | 11.57 | |
APLS | Apellis Pharmaceuticals, Inc. | 01/15/2025 | 01/27/2025 | 19.86% | 90,832,650 | 18,039,735 | 2,522,912 | 7.15 | |
APLS | Apellis Pharmaceuticals, Inc. | 12/31/2024 | 01/10/2025 | 24.35% | 88,205,961 | 21,477,949 | 2,152,590 | 9.98 | |
APLS | Apellis Pharmaceuticals, Inc. | 12/13/2024 | 12/24/2024 | 22.69% | 88,205,961 | 20,011,664 | 3,061,511 | 6.54 | |
APLS | Apellis Pharmaceuticals, Inc. | 11/29/2024 | 12/10/2024 | 24.73% | 88,205,961 | 21,811,296 | 4,485,961 | 4.86 | |
APLS | Apellis Pharmaceuticals, Inc. | 11/15/2024 | 11/26/2024 | 26.28% | 88,205,961 | 23,182,889 | 4,450,930 | 5.21 | |
APLS | Apellis Pharmaceuticals, Inc. | 10/31/2024 | 11/11/2024 | 23.57% | 88,205,961 | 20,786,277 | 2,084,705 | 9.97 | |
APLS | Apellis Pharmaceuticals, Inc. | 10/15/2024 | 10/24/2024 | 23.91% | 88,205,961 | 21,088,064 | 3,827,807 | 5.51 | |
APLS | Apellis Pharmaceuticals, Inc. | 09/30/2024 | 10/09/2024 | 17.30% | 88,205,961 | 15,260,698 | 2,289,442 | 6.67 | |
APLS | Apellis Pharmaceuticals, Inc. | 09/13/2024 | 09/24/2024 | 17.33% | 88,205,961 | 15,284,852 | 1,397,862 | 10.93 | |
APLS | Apellis Pharmaceuticals, Inc. | 08/30/2024 | 09/11/2024 | 18.34% | 88,205,961 | 16,173,529 | 826,033 | 19.58 | |
APLS | Apellis Pharmaceuticals, Inc. | 08/15/2024 | 08/26/2024 | 18.44% | 88,205,961 | 16,267,681 | 2,141,166 | 7.6 | |
APLS | Apellis Pharmaceuticals, Inc. | 07/31/2024 | 08/09/2024 | 18.04% | 88,205,961 | 15,916,603 | 1,373,160 | 11.59 | |
APLS | Apellis Pharmaceuticals, Inc. | 07/15/2024 | 07/24/2024 | 17.28% | 87,805,188 | 15,168,402 | 1,352,038 | 11.22 | |
APLS | Apellis Pharmaceuticals, Inc. | 06/28/2024 | 07/10/2024 | 16.87% | 87,805,188 | 14,814,085 | 1,802,742 | 8.22 | |
APLS | Apellis Pharmaceuticals, Inc. | 06/14/2024 | 06/26/2024 | 15.83% | 87,805,188 | 13,899,907 | 872,302 | 15.93 | |
APLS | Apellis Pharmaceuticals, Inc. | 05/31/2024 | 06/11/2024 | 14.94% | 87,805,188 | 13,116,801 | 1,415,017 | 9.27 | |
APLS | Apellis Pharmaceuticals, Inc. | 05/15/2024 | 05/24/2024 | 14.33% | 87,805,188 | 12,586,479 | 1,669,061 | 7.54 | |
APLS | Apellis Pharmaceuticals, Inc. | 04/30/2024 | 05/09/2024 | 14.11% | 87,805,188 | 12,388,136 | 1,736,373 | 7.13 | |
APLS | Apellis Pharmaceuticals, Inc. | 04/15/2024 | 04/24/2024 | 12.16% | 87,733,401 | 10,669,213 | 1,147,476 | 9.3 | |
APLS | Apellis Pharmaceuticals, Inc. | 03/28/2024 | 04/09/2024 | 10.05% | 103,890,033 | 10,439,851 | 1,098,740 | 9.5 | |
APLS | Apellis Pharmaceuticals, Inc. | 03/15/2024 | 03/26/2024 | 10.19% | 103,890,033 | 10,591,406 | 1,391,553 | 7.61 | |
APLS | Apellis Pharmaceuticals, Inc. | 02/29/2024 | 03/11/2024 | 9.69% | 103,890,033 | 10,064,166 | 1,408,971 | 7.14 | |
APLS | Apellis Pharmaceuticals, Inc. | 02/15/2024 | 02/27/2024 | 10.09% | 101,808,229 | 10,270,787 | 1,503,091 | 6.83 | |
APLS | Apellis Pharmaceuticals, Inc. | 01/31/2024 | 02/09/2024 | 10.48% | 101,808,229 | 10,669,463 | 1,568,794 | 6.8 | |
APLS | Apellis Pharmaceuticals, Inc. | 01/12/2024 | 01/24/2024 | 11.82% | 101,808,229 | 12,034,038 | 2,288,740 | 5.26 | |
APLS | Apellis Pharmaceuticals, Inc. | 12/29/2023 | 01/10/2024 | 11.48% | 101,808,229 | 11,688,661 | 1,792,077 | 6.52 | |
APLS | Apellis Pharmaceuticals, Inc. | 12/15/2023 | 12/27/2023 | 12.75% | 101,808,229 | 12,977,948 | 3,887,528 | 3.34 | |
APLS | Apellis Pharmaceuticals, Inc. | 11/30/2023 | 12/11/2023 | 14.99% | 101,808,229 | 15,264,853 | 1,464,068 | 10.43 | |
APLS | Apellis Pharmaceuticals, Inc. | 11/15/2023 | 11/27/2023 | 15.85% | 101,808,229 | 16,137,939 | 2,143,822 | 7.53 | |
APLS | Apellis Pharmaceuticals, Inc. | 10/31/2023 | 11/09/2023 | 15.94% | 101,808,229 | 16,231,193 | 1,694,169 | 9.58 | |
APLS | Apellis Pharmaceuticals, Inc. | 10/13/2023 | 10/24/2023 | 18.40% | 101,045,573 | 18,593,076 | 2,940,235 | 6.32 |
À la recherche des actions les plus vendues à découvert?